Clear­side Bio los­es near­ly half its val­ue pre-mar­ket as lead eye drug fails piv­otal test

Eye drug de­vel­op­er Clear­side Bio­med­ical $CSLD said late-stage da­ta showed its ex­per­i­men­tal treat­ment, Xipere, did not in­duce an ad­di­tion­al ben­e­fit when used in tan­dem with Re­gen­eron’s $REGN flag­ship Eylea in pa­tients with reti­nal vein oc­clu­sion (RVO), a com­mon cause of sud­den, pain­less, loss of vi­sion in one eye.

This Phase III fail­ure has prompt­ed the com­pa­ny to aban­don the de­vel­op­ment of a Xipere (for­mer­ly supra­choroidal CLS-TA) com­bi­na­tion ther­a­py for RVO, and sent its shares plum­met­ing 46% in pre-mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER